Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

HRTX

Heron Therapeutics Inc

May 01 • 04:00PM ET

2.34

Dollar change +0.02
Percentage change 0.86	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWM IWO SCHA VTWO VHT ITOT IWC FESM

Index	RUT	P/E	-	EPS (ttm)	-0.87	Insider Own	5.10%	Shs Outstand	150.29M	Perf Week	-11.70%
Market Cap	351.77M	Forward P/E	-	EPS next Y	-0.06	Insider Trans	4.21%	Shs Float	142.66M	Perf Month	-8.24%
Income	-110.56M	PEG	-	EPS next Q	-0.07	Inst Own	71.10%	Short Float	17.83%	Perf Quarter	-2.90%
Sales	127.04M	P/S	2.77	EPS this Y	71.29%	Inst Trans	7.15%	Short Ratio	11.34	Perf Half Y	271.43%
Book/sh	-0.23	P/B	-	EPS next Y	72.89%	ROA	-46.70%	Short Interest	25.43M	Perf Year	-3.70%
Cash/sh	0.53	P/C	4.37	EPS next 5Y	47.50%	ROE	-2408.88%	52W Range	0.50 - 3.22	Perf YTD	37.65%
Dividend Est.	-	P/FCF	-	EPS past 5Y	20.01%	ROI	-77.54%	52W High	-27.33%	Beta	1.73
Dividend TTM	-	Quick Ratio	1.84	Sales past 5Y	17.85%	Gross Margin	48.75%	52W Low	368.00%	ATR (14)	0.21
Dividend Ex-Date	-	Current Ratio	2.37	EPS Y/Y TTM	49.36%	Oper. Margin	-87.07%	RSI (14)	36.90	Volatility	7.05% 7.41%
Employees	126	Debt/Eq	-	Sales Y/Y TTM	17.99%	Profit Margin	-87.02%	Recom	1.25	Target Price	6.75
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	57.19%	Payout	-	Rel Volume	0.97	Prev Close	2.32
Sales Surprise	9.63%	EPS Surprise	54.49%	Sales Q/Q	14.00%	Earnings	May 07 BMO	Avg Volume	2.24M	Price	2.34
SMA20	-13.14%	SMA50	-14.06%	SMA200	29.94%	Trades		Volume	2,174,949	Change	0.86%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-23-24	Initiated	CapitalOne	Overweight	$6
Mar-13-24	Reiterated	Needham	Buy	$4 → $5
May-27-20	Initiated	Guggenheim	Buy	$24
Feb-20-20	Reiterated	Needham	Buy	$50 → $48
Jan-16-19	Reiterated	Needham	Buy	$66 → $64
Apr-05-18	Initiated	Evercore ISI	Outperform	$56
Mar-19-18	Reiterated	Mizuho	Buy	$28 → $35
Mar-01-18	Reiterated	Needham	Buy	$28 → $30
Jan-03-18	Initiated	Leerink Partners	Outperform	$22
Sep-27-17	Initiated	Northland Capital	Outperform	$40
Feb-27-17	Initiated	Needham	Buy	$28
Oct-26-16	Initiated	Aegis Capital	Buy
Sep-06-16	Resumed	Lake Street	Buy	$45
May-03-16	Initiated	Cantor Fitzgerald	Buy
Dec-10-15	Initiated	Lake Street	Buy	$45
Sep-23-15	Reiterated	Leerink Partners	Outperform	$38 → $57
Sep-02-15	Initiated	BofA/Merrill	Buy	$46
Aug-03-15	Reiterated	Brean Capital	Buy	$40 → $45
Jun-30-15	Reiterated	JMP Securities	Mkt Outperform	$25 → $33
Jun-19-15	Reiterated	Leerink Partners	Outperform	$26 → $38

Show Previous Ratings

Apr-30-24 10:01AM	Will Heron Therapeutics (HRTX) Report Negative Earnings Next Week? What You Should Know (Zacks) -7.20%
Apr-24-24 08:00AM	Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 (PR Newswire) -5.36%
Apr-11-24 04:05PM	Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City (PR Newswire) +7.69%
Mar-28-24 04:05PM	Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-13-24 09:19AM	Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2023 Earnings Call Transcript (Insider Monkey) +27.54%
07:04AM	Loading…
07:04AM	Q4 2023 Heron Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-12-24 06:00PM	Compared to Estimates, Heron Therapeutics (HRTX) Q4 Earnings: A Look at Key Metrics (Zacks)
05:33PM	Heron Therapeutics Inc (HRTX) Exceeds Full-Year Revenue Guidance for 2023 (GuruFocus.com)
04:34PM	Heron Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
Mar-07-24 09:15AM	Curious about Heron Therapeutics (HRTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
Feb-28-24 08:00AM	Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024 (PR Newswire)
Feb-23-24 11:56AM	12 Best Rising Penny Stocks To Buy (Insider Monkey)
Feb-06-24 12:00PM	All You Need to Know About Heron Therapeutics (HRTX) Rating Upgrade to Strong Buy (Zacks)
Jan-25-24 06:44AM	Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion (Zacks)
01:47PM	Loading…
Jan-24-24 01:47PM	Heron Therapeutics' Non-Opioid, Post-Operative Pain Drug Approved For Use In Additional Orthopedic, Soft Tissue Procedures - FDA Gives Nod (Benzinga) +18.86%
Jan-23-24 08:00PM	Heron Therapeutics Announces FDA Approval of ZYNRELEF Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures (PR Newswire) -5.98%
Jan-15-24 04:51PM	The 3 Most Undervalued Biotech Stocks to Buy in January (InvestorPlace)
09:55AM	Heron Therapeutics (HRTX) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Jan-07-24 05:00PM	Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain (PR Newswire)
Dec-10-23 12:23PM	Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master (Associated Press Finance)
Dec-06-23 11:55AM	13 Hot Penny Stocks To Buy According to Hedge Funds (Insider Monkey)
Nov-28-23 07:33PM	Penny Stock Powerhouses: 7 Picks Poised for Explosive Growth (InvestorPlace) -7.95%
Nov-15-23 10:17AM	Heron Therapeutics Inc (HRTX) Raises 2023 Sales Guidance and Projects Positive EBITDA in 2024 (GuruFocus.com) +59.26%
08:51AM	Heron Therapeutics, Inc. (NASDAQ:HRTX) Q3 2023 Earnings Call Transcript (Insider Monkey)
08:46AM	Q3 2023 Heron Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-14-23 06:00PM	Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
04:17PM	Heron Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial Guidance (PR Newswire)
Nov-07-23 04:05PM	Heron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023 (PR Newswire) +6.88%
09:29AM	Loading…
Aug-24-23 09:29AM	11 Best Long-Term Penny Stocks to Buy Now (Insider Monkey)
Aug-15-23 01:30PM	Heron Therapeutics (HRTX) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks) +10.93%
12:48PM	Heron Therapeutics, Inc. (NASDAQ:HRTX) Q2 2023 Earnings Call Transcript (Insider Monkey)
09:47AM	Q2 2023 Heron Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-23 04:29PM	Heron Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) -6.79%
04:05PM	Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates (PR Newswire)
Aug-07-23 04:05PM	Heron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023 (PR Newswire)
10:50AM	Insiders Pour Millions Into These 2 Stocks Under $10 Heres Why Wall Street Thinks They Could Double (or More) (TipRanks)
Jul-26-23 01:30PM	Northland Capital Markets Institutional Investor Conference (ACCESSWIRE) +9.27%
Jul-24-23 09:02AM	Heron Therapeutics Announces Cost Reduction Plan and Restructuring (PR Newswire) +11.59%
09:00AM	Heron Therapeutics Announces $30 Million Private Placement Financing (PR Newswire)
Jun-23-23 04:05PM	Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer (PR Newswire)
Jun-12-23 09:00AM	Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer (PR Newswire)
May-11-23 05:15PM	Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -8.98%
04:12PM	Heron Therapeutics: Q1 Earnings Snapshot (AP Finance)
04:01PM	Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates (PR Newswire)
May-05-23 12:28PM	Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel (Simply Wall St.)
Apr-20-23 11:45AM	These 2 Growth Stocks Might Be Incredibly Undervalued Right Now (Motley Fool) -5.56%
09:00AM	Heron Therapeutics Announces Commercial Leadership Changes (PR Newswire)
Apr-17-23 04:05PM	Heron Therapeutics Announces Presentation at 22nd Annual Needham Virtual Healthcare Conference (PR Newswire) +5.13%
Apr-06-23 03:42PM	Why Heron Therapeutics Stock Has Been on Fire This Week (Motley Fool) +20.00%
02:01PM	Why Shares of Heron Therapeutics Jumped Thursday (Motley Fool)
Apr-03-23 09:00AM	Heron Therapeutics Announces New CEO and Board Chairman (PR Newswire) +17.88%
Mar-27-23 07:12AM	Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2022 Earnings Call Transcript (Insider Monkey) -9.19%
Mar-24-23 06:43AM	Q4 2022 Heron Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -7.75%
Mar-23-23 09:28PM	Dow futures tick higher, banking crisis weighs (Investing.com)
05:35PM	Heron Therapeutics (HRTX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates (PR Newswire)
Mar-13-23 09:00AM	Heron Therapeutics Announces Centers for Medicare & Medicaid Services (CMS) Granted Pass-through Payment Status for APONVIE, Effective April 1, 2023 (PR Newswire) +11.11%
Mar-10-23 04:05PM	Heron Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 23, 2023 (PR Newswire) -5.68%
Mar-06-23 09:00AM	Heron Therapeutics Announces U.S. Commercial Launch of APONVIE for the Management of Postoperative Nausea and Vomiting in Adults (PR Newswire)
Feb-27-23 04:30PM	Heron Therapeutics Announces Presentation at 43rd Annual Cowen Healthcare Conference (PR Newswire)
Feb-22-23 09:00AM	Heron Therapeutics Enters into Cooperation Agreement with Rubric Capital and Velan Capital (PR Newswire) +10.88%
Jan-30-23 05:54AM	The past three years for Heron Therapeutics (NASDAQ:HRTX) investors has not been profitable (Simply Wall St.)
Jan-09-23 08:30AM	Heron Therapeutics Highlights Progress in Acute Care and Oncology Care Franchises (PR Newswire)
Dec-29-22 09:45AM	Heron Therapeutics Files For Expanded Use Of Zynrelef In Soft Tissue, Orthopedic Surgical Procedures (Benzinga) +9.78%
09:00AM	Heron Therapeutics Announces Filing of an Efficacy Supplement for ZYNRELEF® and Provision in Newly Passed Congressional Bill Anticipated to Provide Separate Reimbursement Outside of the Packaged Surgical Payment for ZYNRELEF (PR Newswire)
Dec-28-22 12:32PM	15 Most Shorted Stocks Hedge Funds Are Buying (Insider Monkey)
Dec-20-22 03:41PM	12 Best Affordable Stocks to Buy Under $5 (Insider Monkey)
Nov-21-22 04:05PM	Heron Therapeutics Announces Virtual Presentation at Evercore ISI 5th Annual HealthCONx Conference (PR Newswire)
Nov-15-22 10:14PM	7 Penny Stocks to Buy for 10-Bagger Returns (InvestorPlace)
Nov-10-22 05:44AM	Heron Therapeutics Third Quarter 2022 Earnings: In Line With Expectations (Simply Wall St.)
Nov-09-22 01:15PM	Analysts Cut Price Targets As Heron Therapeutics' Zynrelef Disappoints In Q3 (Benzinga) -12.75%
Nov-08-22 06:25PM	Heron Therapeutics (HRTX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Highlights Recent Corporate Updates (PR Newswire)
Nov-04-22 11:48AM	Hurry! 7 Pitiful Stocks to Sell Before 2022 Ends (InvestorPlace)
Nov-01-22 04:05PM	Heron Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022 (PR Newswire)
Sep-26-22 09:45AM	4 No-Brainer Penny Stocks to Buy if You Have Money to Invest (InvestorPlace)
Sep-23-22 09:19AM	10 Most Shorted Stocks in September (Insider Monkey) -7.66%
07:30AM	7 Unknown Biotech Stocks That Could Rocket in 2023 (InvestorPlace)
Sep-19-22 06:42AM	FDA Approves Heron Therapeutics' Post-Op Nausea Treatment (Benzinga)
Sep-16-22 02:49PM	Heron Therapeutics Announces U.S. FDA Approval of APONVIE (HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV) (PR Newswire)
Sep-12-22 07:37AM	3 Stocks Expecting Good News From the FDA (Motley Fool)
Aug-23-22 12:00PM	All You Need to Know About Heron Therapeutics (HRTX) Rating Upgrade to Buy (Zacks)
Aug-15-22 09:55AM	How Much Upside is Left in Heron Therapeutics (HRTX)? Wall Street Analysts Think 91% (Zacks)
Aug-09-22 02:10PM	Heron Shares Jump After Equity Financing, Q2 Earnings (Benzinga) +15.13%
09:15AM	Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:01AM	Heron Therapeutics Announces $76.5 Million Private Placement Financing (PR Newswire)
08:00AM	Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Highlights Recent Corporate Updates (PR Newswire)
Aug-02-22 04:05PM	Heron Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022 (PR Newswire)
Jul-21-22 06:32AM	Heron Therapeutics (NASDAQ:HRTX) shareholders have endured a 83% loss from investing in the stock three years ago (Simply Wall St.)
Jul-18-22 06:00PM	7 Biotech Stocks to Buy for Q3 (InvestorPlace)
Jun-30-22 08:41AM	Heron Therapeutics to cut about one-third of its workforce as part of cost-cutting plan (MarketWatch) -11.99%
08:30AM	Heron Therapeutics Announces Restructuring and Cost Reduction Plan to Address Market Dynamics and Prepare for Long-Term Sustainability (PR Newswire)
Jun-14-22 08:30AM	Heron Therapeutics Announces Publication Showing ZYNRELEF® as the Foundation of a Perioperative Non-Opioid Multimodal Analgesic Regimen Reduced Severe Pain and Opioid Use in Patients Undergoing Total Knee Arthroplasty (PR Newswire)
May-26-22 04:05PM	Heron Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference (PR Newswire)
May-16-22 04:05PM	Heron Therapeutics Presents ZYNRELEF® Data at the Society for Obstetric Anesthesia and Perinatology 54th Annual Meeting (PR Newswire)
May-09-22 06:45PM	Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -12.17%
04:05PM	Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Recent Corporate Updates (PR Newswire)
May-03-22 04:05PM	Heron Therapeutics to Report First Quarter 2022 Financial Results on Monday, May 9, 2022 (PR Newswire)

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Forbes William P	EVP, Chief Development Officer	Nov 17 '23	Buy	1.09	25,000	27,250	79,000	Nov 21 12:19 PM
Collard Craig A	Chief Executive Officer	Nov 16 '23	Buy	0.92	150,000	137,970	186,496	Nov 17 12:37 PM
Duarte Ira	EVP, Chief Financial Officer	Nov 16 '23	Buy	0.89	85,000	75,599	85,000	Nov 17 12:36 PM
Forbes William P	EVP, Chief Development Officer	Nov 16 '23	Buy	0.94	50,000	46,995	54,000	Nov 20 10:07 AM
Morgan Adam	Director	Jul 21 '23	Buy	1.37	2,486,744	3,406,839	6,986,744	Jul 25 04:22 PM

Open in Screener

ALIM

Alimera Sciences Inc.

May 01 • 04:00PM ET

3.46

Dollar change -0.22
Percentage change -5.98	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

ALIM Alimera Sciences Inc. daily Stock Chart

Held by: VXF VTI

Index	-	P/E	-	EPS (ttm)	-2.16	Insider Own	9.92%	Shs Outstand	52.35M	Perf Week	-4.68%
Market Cap	181.20M	Forward P/E	16.88	EPS next Y	0.20	Insider Trans	0.00%	Shs Float	47.18M	Perf Month	-12.41%
Income	-21.39M	PEG	-	EPS next Q	-0.06	Inst Own	92.09%	Short Float	0.24%	Perf Quarter	-5.21%
Sales	80.75M	P/S	2.24	EPS this Y	98.73%	Inst Trans	0.43%	Short Ratio	1.57	Perf Half Y	5.17%
Book/sh	0.88	P/B	3.92	EPS next Y	2150.00%	ROA	-20.53%	Short Interest	0.11M	Perf Year	95.48%
Cash/sh	0.23	P/C	14.99	EPS next 5Y	-	ROE	-158.76%	52W Range	1.56 - 4.38	Perf YTD	-19.91%
Dividend Est.	-	P/FCF	-	EPS past 5Y	21.42%	ROI	-18.97%	52W High	-21.00%	Beta	1.20
Dividend TTM	-	Quick Ratio	2.31	Sales past 5Y	13.40%	Gross Margin	75.75%	52W Low	121.79%	ATR (14)	0.24
Dividend Ex-Date	-	Current Ratio	2.39	EPS Y/Y TTM	16.42%	Oper. Margin	-1.82%	RSI (14)	43.80	Volatility	7.77% 6.41%
Employees	159	Debt/Eq	1.46	Sales Y/Y TTM	49.19%	Profit Margin	-26.49%	Recom	1.00	Target Price	8.00
Option/Short	Yes / Yes	LT Debt/Eq	1.44	EPS Q/Q	87.13%	Payout	-	Rel Volume	0.20	Prev Close	3.68
Sales Surprise	8.11%	EPS Surprise	-	Sales Q/Q	87.51%	Earnings	May 14 BMO	Avg Volume	71.59K	Price	3.46
SMA20	-4.89%	SMA50	-6.89%	SMA200	-1.91%	Trades		Volume	14,108	Change	-5.98%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-25-24	Initiated	Maxim Group	Buy	$10
Oct-30-23	Upgrade	Alliance Global Partners	Neutral → Buy	$8
May-28-19	Initiated	Craig Hallum	Buy
Apr-27-17	Initiated	Rodman & Renshaw	Buy	$4
Nov-17-14	Initiated	Summer Street Research	Buy	$12
Sep-29-14	Reiterated	Northland Capital	Outperform	$7 → $10
Oct-28-13	Upgrade	Cowen	Market Perform → Outperform
Oct-08-13	Initiated	Northland Capital	Outperform	$5
Nov-14-11	Downgrade	Rodman & Renshaw	Mkt Outperform → Mkt Perform
Dec-27-10	Reiterated	Oppenheimer	Outperform	$16 → $14
Oct-11-10	Initiated	Rodman & Renshaw	Mkt Outperform	$13
Jun-02-10	Initiated	Oppenheimer	Outperform	$16

Show Previous Ratings

Apr-30-24 08:00AM	Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update (GlobeNewswire)
Mar-20-24 08:00AM	Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-19-24 08:00AM	Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network (GlobeNewswire)
Mar-08-24 10:05AM	Alimera Sciences, Inc. (NASDAQ:ALIM) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-07-24 11:18PM	Q4 2023 Alimera Sciences Inc Earnings Call (Thomson Reuters StreetEvents)
01:55PM	Loading…
01:55PM	Alimera Sciences Inc (ALIM) Reports Significant Revenue Growth in Q4 and Full Year 2023 (GuruFocus.com)
12:52PM	ALIM Stock Earnings: Alimera Sciences Beats Revenue for Q4 2023 (InvestorPlace)
09:00AM	Alimera Sciences (ALIM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:11AM	Alimera Sciences: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results (GlobeNewswire)
Feb-29-24 08:00AM	Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update (GlobeNewswire) +5.99%
Feb-08-24 08:00AM	The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN (GlobeNewswire)
Jan-04-24 08:00AM	Alimera Completes Recruitment for the Synchronicity Study (GlobeNewswire)
Jan-02-24 08:00AM	Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.56%
Dec-12-23 07:30AM	Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:30PM	Loading…
Nov-08-23 04:30PM	Alimera Appoints Maggie A. Pax to Its Board of Directors (GlobeNewswire)
Oct-31-23 08:00AM	Alimera Announces Scientific Data Highlighting ILUVIEN To Be Presented at the American Academy of Ophthalmology (GlobeNewswire)
Oct-27-23 09:26AM	Alimera Sciences, Inc. (NASDAQ:ALIM) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-26-23 09:29AM	Alimera Sciences Inc (ALIM) Reports Q3 2023 Financial Results (GuruFocus.com)
08:30AM	Alimera Sciences (ALIM) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:18AM	Alimera Sciences: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Alimera Sciences Reports Third Quarter 2023 Results (GlobeNewswire)
Oct-16-23 08:00AM	Alimera Sciences to Report Third Quarter 2023 Financial Results on October 26, 2023, and Provide Corporate Update (GlobeNewswire) +14.83%
Oct-11-23 08:00AM	Alimera Announces Multiple Presentations Highlighting ILUVIEN and YUTIQ Data at Retina Society Annual Congress (GlobeNewswire) -5.75%
Oct-03-23 08:00AM	Alimera Sciences Appoints Jason Werner as Chief Operating Officer (GlobeNewswire)
Sep-16-23 03:01AM	Caligan Partners LP Reduces Stake in Alimera Sciences Inc (GuruFocus.com)
Sep-05-23 08:00AM	Alimera Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) -7.04%
Aug-23-23 09:02AM	Altium Capital Management LP Acquires New Stake in Alimera Sciences Inc (GuruFocus.com)
Aug-13-23 04:37AM	Alimera Sciences, Inc. (NASDAQ:ALIM) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 06:21AM	Stonepine Capital Management, LLC Acquires New Stake in Alimera Sciences Inc (GuruFocus.com)
10:00PM	Loading…
Aug-10-23 10:00PM	Q2 2023 Alimera Sciences Inc Earnings Call (Thomson Reuters StreetEvents) +7.03%
08:50AM	Alimera Sciences (ALIM) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:47AM	Alimera Sciences: Q2 Earnings Snapshot (AP Finance)
07:30AM	Alimera Sciences Reports Second Quarter 2023 Results (GlobeNewswire)
Aug-08-23 09:15AM	Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline (Newsfile)
Aug-03-23 07:03PM	Velan Capital Investment Management LP Boosts Stake in Alimera Sciences Inc (GuruFocus.com) +6.45%
Aug-02-23 11:43AM	Alimera Sciences to Report Second Quarter 2023 Financial Results on August 10, 2023, and Provide Corporate Update (GlobeNewswire) -5.20%
Jul-07-23 09:40AM	Are Medical Stocks Lagging 89BIO (ETNB) This Year? (Zacks)
Jun-08-23 08:50AM	Alimera Sciences (ALIM) Is Attractively Priced Despite Fast-paced Momentum (Zacks) -5.15%
Jun-01-23 09:40AM	Are Medical Stocks Lagging Alimera Sciences (ALIM) This Year? (Zacks) -5.09%
May-25-23 10:15AM	Alimera (ALIM) Completes Enrollment in Eye Disease Study (Zacks)
May-24-23 08:00AM	Alimera Completes Recruitment for its Landmark NEW DAY Study (GlobeNewswire) +8.09%
May-23-23 08:50AM	Alimera Sciences (ALIM) Shows Fast-paced Momentum But Is Still a Bargain Stock (Zacks) -7.84%
May-19-23 12:01PM	Alimera (ALIM) Up on Deal With Eyepoint for U.S. Rights to Yutiq (Zacks) -6.50%
May-18-23 10:29PM	Q1 2023 Alimera Sciences Inc Earnings Call (Thomson Reuters StreetEvents) +19.42%
09:02AM	EyePoint Pharma Offloads Its Commercially-Available Eye Implant For $82.5M Plus Royalties (Benzinga)
07:00AM	Alimera Acquires U.S. Commercial Rights to YUTIQ® (GlobeNewswire)
May-17-23 04:05PM	Alimera Sciences to Host Rescheduled Corporate Update Call on Thursday, May 18, 2023, at 8:30am ET (GlobeNewswire) +9.57%
May-15-23 09:05AM	Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:50AM	Alimera Sciences Reports First Quarter 2023 Results (GlobeNewswire)
May-08-23 08:00AM	Alimera Sciences to Report First Quarter 2023 Financial Results on May 15, 2023, and Provide Corporate Update (GlobeNewswire) -5.26%
May-01-23 10:01AM	Will Alimera Sciences (ALIM) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-20-23 08:00AM	Alimera Data to be Featured in Scientific Programming at Upcoming Annual Congress (GlobeNewswire)
Apr-17-23 07:20AM	There's No Escaping Alimera Sciences, Inc.'s (NASDAQ:ALIM) Muted Revenues Despite A 27% Share Price Rise (Simply Wall St.)
Apr-04-23 01:18PM	Alimera Sciences, Inc. (NASDAQ:ALIM) Q4 2022 Earnings Call Transcript (Insider Monkey)
Apr-03-23 08:09AM	When Will Alimera Sciences, Inc. (NASDAQ:ALIM) Breakeven? (Simply Wall St.) -5.24%
08:00AM	Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN® in the Nordic Countries (GlobeNewswire)
Mar-31-23 09:15AM	Alimera Sciences (ALIM) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +17.98%
08:00AM	Alimera Sciences Announces 2022 Financial Results and Business Update (GlobeNewswire)
Mar-27-23 08:00AM	Alimera Improves Capital Structure, Strengthens Balance Sheet and Extends Term Loan Facility (GlobeNewswire) +36.91%
Mar-24-23 04:05PM	Alimera Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 31, 2023, and Provide Corporate Update (GlobeNewswire)
Feb-27-23 08:00AM	Alimera Appoints Roger Sawhney, M.D. to Its Board of Directors (GlobeNewswire)
Feb-22-23 08:00AM	Alimera Announces Submission of Marketing Authorization Application in Switzerland for ILUVIEN® (GlobeNewswire) -5.44%
Jan-09-23 08:00AM	Alimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial Officer (GlobeNewswire)
Dec-29-22 06:02AM	Alimera Sciences, Inc. (NASDAQ:ALIM) Q3 2022 Earnings Call Transcript (Insider Monkey) +10.76%
Dec-08-22 08:00AM	Alimera Sciences Announces Agreement to Extend Amortization Date and Interest-Only Period on Loan Agreement (GlobeNewswire)
Nov-29-22 08:00AM	Alimera Highlights Abstracts Regarding Consensus Among US Retina Specialists and Reduced Retinal Thickness Variability Leading to Improved Visual Outcomes Following ILUVIEN® Administration (GlobeNewswire)
Nov-17-22 03:54PM	7 Stocks That Could Implode at Any Moment (InvestorPlace)
Nov-16-22 05:05AM	Alimera Sciences Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.) -9.38%
Nov-14-22 08:55AM	Alimera Sciences (ALIM) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Alimera Sciences Announces Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-02-22 08:00AM	Alimera Sciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022, and Provide Corporate Update (GlobeNewswire)
Nov-01-22 08:00AM	Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in the Czech Republic (GlobeNewswire)
Oct-20-22 09:40AM	Is Alimera Sciences (ALIM) Stock Outpacing Its Medical Peers This Year? (Zacks)
Oct-18-22 09:03AM	10 Best Low Price Pharma Stocks To Buy Now (Insider Monkey) +6.11%
Oct-06-22 08:00AM	Paladin Phase 4 Study Confirms ILUVIEN® Patients' Reduced Need for Multiple Treatments (GlobeNewswire) +6.81%
Sep-23-22 08:00AM	Alimera Announces Agreement with Jaeb Center for Health Research on Behalf of the DRCR Retina Network (GlobeNewswire)
Sep-20-22 08:00AM	Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Ireland (GlobeNewswire)
Sep-19-22 09:40AM	Are Medical Stocks Lagging Alimera Sciences (ALIM) This Year? (Zacks)
Sep-02-22 09:40AM	Is Humana (HUM) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-31-22 08:48AM	Alimera Announces Multiple Abstracts Highlighting ILUVIEN® Real World Data at EURETINA Annual Congress (GlobeNewswire)
Aug-29-22 08:50AM	Why Fast-paced Mover Alimera Sciences (ALIM) Is a Great Choice for Value Investors (Zacks)
Aug-19-22 08:50AM	Alimera Sciences (ALIM) Is a Great Choice for "Trend" Investors, Here's Why (Zacks) +5.78%
Aug-17-22 09:40AM	Is Alimera Sciences (ALIM) Outperforming Other Medical Stocks This Year? (Zacks)
Aug-10-22 08:00AM	Alimera Sciences to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference (GlobeNewswire)
Aug-09-22 08:00AM	Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Portugal (GlobeNewswire) -5.59%
06:47AM	Investors in Alimera Sciences (NASDAQ:ALIM) from five years ago are still down 68%, even after 32% gain this past week (Simply Wall St.)
Aug-05-22 08:50AM	Here Is Why Bargain Hunters Would Love Fast-paced Mover Alimera Sciences (ALIM) (Zacks)
Aug-01-22 09:40AM	Has Alimera Sciences (ALIM) Outpaced Other Medical Stocks This Year? (Zacks)
Jul-27-22 08:45AM	Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +6.60%
07:30AM	Alimera Sciences Announces Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-26-22 08:00AM	Paladin Phase 4 Study Confirms Safety of Durable ILUVIEN® Treatment and Reduces Burden of Care For DME Patients (GlobeNewswire)
Jul-22-22 10:34AM	Alimera Sciences to Report Second Quarter 2022 Financial Results on Wednesday, July 27, 2022, and Provide Corporate Update (GlobeNewswire)
08:00AM	Alimera Announces Pricing and Reimbursement of Uveitis Indication Granted for ILUVIEN® in France (GlobeNewswire)
Jul-13-22 08:00AM	Alimera Announces Data to Be Highlighted In Scientific Programming At Annual Congress (GlobeNewswire)
Jul-08-22 08:00AM	Alimera Announces Approval and Pricing Granted for ILUVIEN® for Uveitis in Italy (GlobeNewswire)
Jun-24-22 07:10AM	A number of insiders bought Alimera Sciences, Inc. (NASDAQ:ALIM) stock last year, which is great news for shareholders (Simply Wall St.)
Jun-08-22 08:03AM	Phase III Clinical Study IND Accepted in China for Alimeras Fluocinolone Acetonide Intravitreal Implant (GlobeNewswire)
Jun-02-22 08:00AM	Alimera Sciences to Present at the LD Micro Invitational XII Conference (GlobeNewswire)
May-12-22 08:03AM	Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to ILUVIEN® Use for IOP Outcomes (GlobeNewswire)

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Caligan Partners LP	10% Owner	Sep 14 '23	Buy	3.39	579,000	1,962,810	16,835,154	Sep 15 04:05 PM
Caligan Partners LP	10% Owner	Sep 14 '23	Sale	3.39	579,000	1,962,810	16,256,154	Sep 15 04:05 PM
Morgan Adam	Director	May 17 '23	Buy	1.70	1,401,901	2,383,232	1,659,654	May 19 05:17 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

HRTX

Heron Therapeutics Inc

ALIM

Alimera Sciences Inc.

Upgrade your FINVIZ experience